CTCA for CAD Screening in Patients Undergoing TAVR patients referred for TAVR considering its proven diagnostic accuracy, its noninvasiveness, and low-contrast volume need. 6 Moreover, the avoidance of invasive CA in the preoperative patient evaluation before TAVR could be associated with reduced in-hospital stay, referral-to-procedure time, and overall costs.
The aim of the present investigation was to determine the safety of CTCA as a first-line preoperative imaging tool, in terms of major adverse cardiovascular and cerebrovascular events (MACCE), in patients undergoing TAVR.
Methods

Study Population
All patients with severe AS treated with TAVR at our hospital from November 2007 to September 2013 were retrospectively analyzed. Indication for TAVR was discussed in a multidisciplinary group (heart team) consisting of interventional cardiologists, cardiac surgeons, echocardiographists, cardiovascular radiologists, and cardioanesthetists. In particular, all patients with severe AS deemed unsuitable or at high risk for surgical valve replacement were screened for TAVR. Eligibility was based mainly on available risk scores (Society of Thoracic Surgeons score and logistic EuroSCORE) in addition to other parameters not included in these scores, like porcelain or severely atherosclerotic aorta, frailty, severe liver disease/cirrhosis, and hostile chest. 7 The preoperative diagnostic flowchart routinely applied in our center is illustrated in Figure 1 .
CT/CTCA scan was used to assess aortic valve anatomy and calcification, aortic root size, left ventricular outflow track calcifications, height of the coronary ostia from the aortic annular plane, peripheral vascular access sites, and coronary artery anatomy. CT/CTCA was not performed only in patients with specific contraindications such as (1) severe chronic kidney disease (GFR<30 mL/min per 1.73 m 2 ) or (2) cardiac tachyarrhythmia not allowing gating.
After successful CT/CTCA scan, an invasive coronary vasculature assessment was performed in the case of (1) need to characterize a suspicious critical coronary lesion at CTCA or (2) failure to assess coronary anatomy properly at CTCA because of severe coronary calcifications or moving artifacts. Invasive CA was performed either before or at the same time of TAVR. Finally, identification at CA of a critical coronary lesion in a proximal segment of a major epicardial vessel led to subsequent percutaneous coronary intervention (PCI) before to or at the same time of TAVR ( Figure 1 ).
In this study, patients who underwent TAVR without performing CT/CTCA were excluded from the study cohort. According to the preoperative imaging modality used, the study population was divided into 2 groups ( Figure 2 ): group A: patients who were assessed only with cardiac CT/ CTCA (375/491) and group B: patients who were assessed with both cardiac CT/CTCA and invasive CA (116/491).
Patients who underwent TAVR without performing CT/CTCA were excluded from the study cohort. A written informed consent was obtained from all the patients included in the study population. This study obtained institutional review board approval.
CTCA Acquisition and Contrast Medium Injection Protocols
All CT angiography examinations were performed using a 64-slice CT system (LightSpeed VCT XTE scanner, GE Healthcare). For CT angiography, retrospectively gated scanning of the thorax and the abdomen was performed; ECG dose modulation was used. Tube voltage and current were adapted to patients' body mass index (100-120 kV; 450-350 mA). All the scanning parameters are described in Table I in the online-only Data Supplement. Our contrast medium injection protocol is reported in Appendix in the online-only Data Supplement.
TAVR Procedure
Patients included in this analysis underwent TAVR through transfemoral, transapical, transaortic, or transaxillary approach. TAVR devices used include Edwards (Edwards Lifesciences, Irvine, CA) Sapien Valve, Sapien XT Valve, Medtronic (Medtronic Inc, Minneapolis, MN) CoreValve, and Direct Flow Medical Transcatheter Aortic Valve (DirectFlow Medical, Santa, Rosa, CA). The valve of choice was at the discretion of the operator according to patient's anatomy. All patients gave written informed consent for the procedure and data collection.
WHAT IS KNOWN
• Severity of coronary artery disease is associated with worse mid-and long-term outcomes after transcatheter aortic valve replacement.
• Preprocedural screening of coronary artery disease before transcatheter aortic valve replacement is recommended.
• Invasive coronary angiography is usually performed before transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• Pre-transcatheter aortic valve replacement coronary artery disease screening can be safely carried out through computed tomographic coronary angiography at the time of cardiac computed tomographic scan, allowing with a single test the acquisition of a wide range of information on aortic annulus, peripheral access sites, and coronary artery anatomy.
• The role of computed tomographic coronary angiography in pre-transcatheter aortic valve replacement coronary artery disease screening must be tested in appropriately designed prospective studies. 
Study Objectives
The primary objective of our study was to assess the incidence of MACCE at 30 days and 1 year after TAVR. MACCE was defined as the composite of death, myocardial infarction, ischemia-driven revascularization, and cerebrovascular events. 8 Our primary hypothesis was that the use of CTCA as a fist-line imaging tool is not associated with an increased incidence of ischemic adverse cardiovascular and cerebrovascular events after TAVR when compared with patients who underwent invasive coronary anatomy assessment by means of CA.
Other TAVR-related outcomes have been assessed according Valve Academic Research Consortium-2 criteria. 7 Composite end points included device success, early safety at 30 days, and clinical efficacy at 1 year. Valve Academic Research Consortium-2 composite end points are described elsewhere. 7
Statistical Analysis
Demographic data are presented for each of the 2 cardiovascular imaging groups, CTCA-only (group A) and CTCA+CA (group B). Continuous variables are expressed as mean±SD or as median and quartiles as appropriate. Differences between continuous variables were tested by means of Student t test or Wilcoxon signed-rank test as appropriate. Categorical variables are expressed in percentages (%) and were compared by means of χ 2 test or the Fisher exact. Unadjusted survival analysis was performed using Kaplan-Meier analysis and Log-rank test. Because of the nonrandomized design of this study, to reduce the influence of confounding bias, we performed an adjusted analysis for the 30-day and 1-year outcomes by means of Cox-regression analysis, after the definition of a multivariable model. In particular, all the variables which were statistically different among baseline and procedural characteristics or those considered clinically relevant were included in the multivariable model. Candidate covariates to be included in the multivariable model were age, sex, body mass index, previous revascularization, CAD, chronic kidney disease, chronic obstructive pulmonary disease, porcelain aorta, left ventricular ejection fraction, mitral regurgitation ≥2+/3+, procedural access, and learning curve (the study period divided in tertiles). Results from the adjusted analysis were expressed by mean of hazard ratios, their corresponding 95% confidence intervals, and P values. All statistical analyses were performed using IBM SPSS (Chicago, IL) version 21. A 2-sided P value of <0.05 was considered statistically significant.
Results
Overall, 536 patients treated with TAVR were included in the study cohort. Of these, 491 of 536 (91.6%) underwent multimodality imaging assessment including transthoracic or transesophageal echocardiography and cardiac CT/CTCA. CT/CTCA was not performed in 45 of 536 patients (8.3%) because of severe chronic kidney disease (GFR<30 mL/min per 1.73 m 2 ) or cardiac tachyarrhythmia not allowing gating. These patients underwent TAVR only performing transthoracic or transesophageal echocardiography and invasive CA as preoperative imaging tests.
Of the 491 patients who underwent CT/CTCA, 470 (96%) of CTCA were interpretable. Conversely, 116 (24%) performed also CA for one of the following reasons: (1) characterization of a suspicious critical coronary lesion at CTCA (65/116; 56%), (2) failure to assess coronary anatomy properly at CTCA because of severe coronary calcifications or moving artifacts (21/116; 18%); and (3) CA performed in the previous 6 months either for diagnosis of CAD or PCI (30/116; 26%).
Among patients who underwent invasive CA for characterization of a suspicious coronary lesion at CTCA, 31 (47.7%) had a coronary lesion deemed hemodynamically significant. Of them, 16 patients underwent PCI concomitantly to TAVR procedure, whereas 6 patients underwent PCI during the same hospitalization or 3 months after TAVR. The remainder of patients (n=9) were left untreated as the stenosis did not occur in a proximal segment of a major epicardial vessel.
Baseline Characteristics
Baseline characteristics in the 2 groups are reported in Table 1 . Patients in group A had a higher prevalence of chronic kidney disease (37.6% versus 25.9%; P=0.02). Conversely, patients in group B had higher prevalence of previous PCI (18.1% versus 27.6%; P=0.03), CAD (40.5% versus 62.1%; P<0.01), and porcelain aorta (12% versus 25%; P<0.01).
Procedural Characteristics
Procedural characteristics are illustrated in Table 2 . Patients in group A were more commonly treated by transfemoral access. No differences were present in the use of a balloon-expandable or self-expandable devices, sheath sizes, volume of contrast used, and radiation dose. Conversely, a trend to longer procedural time was observed in group B.
Unadjusted 30-Day and 1-Year Valve Academic Research Consortium-2 Outcomes
Unadjusted 30-day and 1-year outcomes according to Valve Academic Research Consortium-2 definitions are reported in Table 3 . We found no differences in MACCE rates at 30 days (4% versus 5.2%; P=0.42) and 1-year (15.4% versus 18.1%; P=0.61) between groups A and B. Device success composite end point was significantly higher in group A (75.2% versus 65.5%; P=0.04). Four events of in-hospital myocardial infarction were observed in group A, whereas 2 events were observed in group B (1.1% versus 1.7%; P=0.57). Among the 6 events, 2 were because of coronary artery occlusion. One case occurred immediately after postdilation of an Edwards Sapien XT 23 mm, whereas the other case occurred several hours after the procedure (implantation of an Edwards Sapien XT 23 mm postdilated) because of late dissection of the left main coronary artery. In the remainder 4 cases, there was no evidence of significant coronary lesion at urgent CA.
No differences were observed in postprocedural discharge days (6 [5-8] versus 6 [5] [6] [7] [8] ; P=0.34) between groups, conversely a shorter overall in-hospital stay (in-hospital admission to final discharge) was observed in group A (9 [7-14] versus 10 [8-16]; P=0.04). There were no differences in in-hospital stay (days) among patients in group B who performed or did not perform PCI (12 [7.5-16] versus 10 [7] [8] [9] [10] [11] [12] [13] [14] [15] ; P=0.85).
Finally, no differences in all-cause mortality, cardiovascular mortality, and the clinical efficacy end point were observed at 1 year of follow-up.
Adjusted 30-Day and 1-Year Outcomes
After multivariable adjustment for baseline and procedural confounders, there were still no differences in 30-day and 1-year outcomes ( Table 4 ) between groups. CTCA performed as the only preoperative CAD screening test (group A) was not associated with increased risk of MACCE at 30 days (hazard ratio, 1.08; 95% confidence interval, 0.44-2.70; P=0.87) and at 1 year (hazard ratio, 0.89; 95% confidence interval, 0.49-1.60; P=0.69). Unadjusted survival-free curves from MACCE are illustrated in Figure 3 .
Discussion
The results of the present investigation show that CTCA seems effective and safe for preoperative CAD screening in patients referred for TAVR. The use of CTCA as the only CAD screening tool was not associated with a higher incidence of 30-day and 1-year MACCE at crude and adjusted analysis. Moreover, patients in whom invasive CA was not performed had shorter overall in-hospital stay.
Appropriate patient and device selection has been demonstrated to have a critical influence on clinical outcomes after TAVR. 9 Patients referred for TAVR are generally elderly and affected by multiple cardiovascular comorbidities. CAD complexity demonstrated to be associated with impaired clinical outcomes at 1 year after TAVR. 3 Thus, identification and adequate treatment of CAD must be carefully evaluated before the procedure. [10] [11] [12] Results reported as n (%), mean±SD or median, and quartiles (Q1 and Q3), as appropriate. Results reported as n (%) or mean±SD as appropriate. AVA indicates aortic valve area; BMI, body mass index; CABG, coronary artery by-pass graft; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; logistic EuroSCORE, European system for cardiac operative risk evaluation; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; MI, myocardial infarction; NYHA, New York Heart Association class; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; and STS, Society of Thoracic Surgeons.
*CKD was defined as eGFR<60 mL/min by MDRD formula. CTCA for CAD Screening in Patients Undergoing TAVR Although CA remains the gold standard for the assessment of coronary anatomy, 5 CTCA is a viable, noninvasive alternative. 13 Accordingly, several studies have been performed comparing the sensitivity and specificity of CTCA in detecting hemodynamically significant coronary lesions. 6 Previous studies using CT scanners equipped with 4 detectors reported a moderate sensitivity (81±7.2%) and good specificity (91±0.9%) compared with CA for detection of coronary stenosis. 14 More recent studies using 64-slice CT have shown higher sensitivity (86%-94%) and specificity (93%-97%) for the detection of stenosis even in smaller arteries and side branches in patients at intermediate risk. 15 In the latter studies, the negative predictive value of CTCA was 95% to 97%, suggesting that it is reliable in ruling out the presence of significant coronary stenosis. Furthermore, some studies have compared the stenosis severity detected by coronary CTCA with that measured with CA. The overall agreement between the 2 diagnostic approaches seems to be moderate. The sensitivities of 64-slice CT for the assessment of <50% stenosis, >50% stenosis, and >75% stenosis have been reported to be 79%, 73%, and 80%, respectively, whereas the overall specificity was 97%. 16 Finally, compared with intravascular ultrasounds, CTCA reported a sensitivity of 83% to 94% and a specificity of 90% to 93%. 17 In addition, CT angiography can provide excellent evaluation of the peripheral vasculature with a relatively low-contrast dose. Recently, the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) study, 18 that randomly assigned 10 003 patients with suspected CAD (with a mean pretest probability of 53.3±21.4%) to either CTCA or functional testing (exercise electrocardiography, nuclear stress testing, or stress echocardiography) found no differences in ischemic outcomes at a median follow-up time of 25 months, suggesting that CTCA is not superior, but also noninferior, to a strategy of functional assessment for CAD. Considering the data described above, a single CT/CTCA scan might provide most of the information needed to perform TAVR. [19] [20] [21] In our center, all patients assessed for TAVR, with the exception of those with specific contraindications, underwent cardiac CT/CTCA as part of preprocedural diagnostic imaging. CA was restricted to patients in whom CT scanning was contraindicated or in whom CTCA had detected coronary lesions requiring further investigation with a view to revascularization.
The rate of periprocedural myocardial infarction in our experience was of 1.2%. This incidence compares similarly with those reported in major trials and registries where an invasive coronary anatomy evaluation was the standard of care. [22] [23] [24] [25] [26] The use of CTCA as the only preoperative assessment tool to evaluate patients undergoing TAVR could raise the doubt that some patients with significant CAD may be missed. However, in both unadjusted and adjusted analysis for baseline and procedural confounders, there was no increased incidence of MACCE at 1 year of follow-up after TAVR.
Avoidance of invasive CA before TAVR may have also an effect on overall in-hospital stay and hospital costs. Of note, overall in-hospital length-of-stay (from hospital admission to hospital discharge) was reduced in group A. Conversely, postprocedural in-hospital days were similar between screening strategies, reflecting similar rates of periprocedural complications between groups. Even if associated hospital costs were not captured in our study, the avoidance of invasive CA and shorter in-hospital stay might allow a significant saving on the overall TAVR costs.
Another point favoring the use of invasive CA in selected patients is the possibility to perform a PCI at the same time of TAVR procedure. In our experience, 16 patients had concomitant PCI at the same time of TAVR procedure after coronary vasculature evaluation by means of invasive CA. Previous data support the safety of concomitant PCI for the treatment of significant coronary lesions at the same time of TAVR procedure. 10 This strategy may also allow a better optimization of costs and patient care avoiding multiple hospitalizations and invasive procedures. The ongoing Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Implantation (ACTIVATION: A Randomized Controlled Trial; ISRCTN75836930) trial will clarify the hypothesis of whether pre-TAVR revascularization is needed. 27 Moreover, the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI; NCT01586910) and Placement of Aortic Transcatheter Valve (PARTNER II; NCT01314313) are including patients with severe AS, CAD, and intermediate risk for surgery. In both studies, TAVR with or without PCI will be compared with surgical aortic valve replacement with or without coronary artery by-pass graft.
In summary, our single-center experience suggests that cardiac CT/CTCA might be a safe and effective noninvasive CAD screening tool in patients with severe AS undergoing assessment for TAVR. Invasive CA could be reserved for patients in whom CT/CTCA is contraindicated, failed to assess coronary anatomy or when a significant proximal coronary artery lesion is detected at CTCA.
Study Limitations
This study has several important limitations that have to be disclosed. First, because of the nonrandomized and retrospective nature of this study, the findings of the present investigation are subject to confounder bias. Second, a retrospective analysis might be not the proper way to compare the efficacy of screening tests for a particular medical condition making our results only hypothesis-generating. Third, the design of this study implies a selection bias as patients who were found to have suspicious coronary lesions underwent invasive CA; therefore, the 2 study comparators may reflect 2 different types of patients within an all-comer real-world TAVR population. Considering these limitations, to prove the role of CTCA as a safe and effective preoperative 1st-line CAD screening test for TAVR patients, appositely designed prospective randomized studies are warranted.
Conclusions
CTCA coupled to cardiac CT scan used as a routine, noninvasive, diagnostic screening tool for CAD in patients with severe AS undergoing TAVR seems to be safe and effective, allowing with a single test the acquisition of a wide range of information on aortic annulus, peripheral access sites, and coronary artery anatomy. Performing CA only when absolutely necessary could lead to improved outcomes, reductions in the overall procedural cost and hospitalization time. However, this hypothesis must be tested in appositely designed prospective studies.
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